This study is designed to investigate the absorption, distribution, metabolism and elimination of a single oral dose of radiolabeled \[14C\]-labeled RO5285119 in healthy male participants.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Masking
NONE
Enrollment
6
Single oral dose of RO5285119 with approximately 2.1 MBq (56.6 uCi) \[14C\]-radiolabeled RO5285119 administered as a drinking solution under fasted conditions on Day -1
Unnamed facility
Zuidlaren, Netherlands
Total recovery of radioactivity over time in urine and feces expressed as a percentage of the total radioactive dose administered
Time frame: Up to Day 17
Pharmacokinetic profile of total drug-related material, RO5285119 and its metabolites, as appropriate in plasma, estimated Cmax
Time frame: Up to Day 17
Percent of dose recovered as total radioactivity, i.e. relative abundance of RO5285119 and its metabolite(s) in plasma, urine and feces
Time frame: Up to Day 17
Incidence of adverse events
Time frame: Up to 28 days after the last dose of study drug
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.